Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Federal funding opportunity RFA-NS-26-030 from National Institutes of Health.
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- February 12, 2026
- Closes
- See announcement
- Program funding
- $6,000,000
- Expected awards
- 3
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.853
- Category
- Health
Program funding history
Awards made under Assistance Listing 93.853 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $1.8B
- FY2025 obligated
- $1.8B
- FY2026 (to date) obligated
- $1B
- Awards in window
- 9,367
Top recipients: The General Hospital Corporation, Regents of the University of California, San Francisco, the, The Johns Hopkins University, Regents of the University of Michigan, The Trustees of Columbia University in the City of New York
Source: USAspending.gov · refreshed July 2026
Synopsis
The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are creating new opportunities to treat, prevent, and potentially modify the course of dementias; however, progress is limited by challenges in delivery, safety, manufacturability, and readiness for clinical testing.
This program is intended to support projects across the translational pipeline, from optimization through IND development and early clinical evaluation, for genomic and biologic therapeutic candidates with compelling preclinical evidence. Eligible projects may include activities to refine therapeutic design and manufacturability; establish pharmacology, toxicology, biodistribution, and in vivo efficacy; to generate the full body of data required to support regulatory interactions and IND submissions, and, when appropriate, first-in-human (FIH) clinical studies.
The program is aligned with priorities from the ADRD Summits, including acceleration of disease-modifying therapeutic development in frontotemporal degeneration (FTD), Lewy body dementia (LBD), and vascular contributions to cognitive impairment and dementia (VCID). Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
Who can apply
- Public housing authorities/Indian housing authorities
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Special district governments
- City or township governments
- State governments
- Independent school districts
- Private institutions of higher education
- Native American tribal governments (Federally recognized)
- For profit organizations other than small businesses
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Small businesses
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.
Similar grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Never miss a funding deadline again
Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.
Get funding alerts